Uniphar (LON:UPR - Get Free Report)'s stock had its "buy" rating restated by equities researchers at Shore Capital in a research note issued to investors on Thursday, Marketbeat.com reports.
Uniphar Price Performance
UPR stock remained flat at GBX 300 ($4.04) during trading on Thursday. The company's stock had a trading volume of 803 shares, compared to its average volume of 32,024. The firm's 50-day simple moving average is GBX 252.20 and its 200 day simple moving average is GBX 211.91. Uniphar has a 1 year low of GBX 163 ($2.19) and a 1 year high of GBX 312 ($4.20). The company has a quick ratio of 0.60, a current ratio of 0.90 and a debt-to-equity ratio of 119.48. The firm has a market cap of £933.85 million, a price-to-earnings ratio of 20.86 and a beta of 0.75.
About Uniphar
(
Get Free Report)
Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.
Read More
Before you consider Uniphar, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Uniphar wasn't on the list.
While Uniphar currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
